How Does IV Acyclovir Treat Neonatal HSV in Babies?

Intravenous (IV) acyclovir is the standard, urgently needed treatment for babies with suspected or confirmed neonatal herpes simplex virus (HSV). Most neonatal HSV is acquired around the time of delivery ^[1]. Acyclovir can be lifesaving; it works by directly targeting the virus and stopping it from copying its DNA ^[2]. By acting as a broken building block in the virus’s assembly line, acyclovir prevents HSV from multiplying and spreading further ^[3]. While it preferentially targets infected cells, it is not completely risk-free and requires close monitoring of the baby’s kidney function and blood counts ^[4].

Interrupting the Viral Assembly Line

When HSV infects a cell, its main goal is to multiply. To do this, the virus must copy its genetic code, or DNA, using a viral enzyme called DNA polymerase ^[2].

Acyclovir is designed to look very similar to the natural building blocks the virus uses to build its DNA ^[4]. However, acyclovir is structurally incomplete. When the viral DNA polymerase mistakenly grabs acyclovir and adds it to the growing DNA chain, the chain can no longer be extended ^[2][5]. This process, called chain termination, shuts down the assembly line and suppresses the production of new virus particles ^[3].

Acyclovir does not directly kill the virus that is already present, nor does it remove the dormant (latent) virus from the body ^[5]. Instead, it drastically halts the production of new viruses ^[5]. This prevents further damage and spread, suppressing active replication while medical care and the baby’s immune system help control the infection ^[1].

The “Lock and Key” Mechanism and Potential Side Effects

Acyclovir has a unique built-in mechanism that helps it target the virus ^[4].

When it enters the baby’s bloodstream through the IV, it is inactive ^[2]. To become active, it requires a specific viral enzyme called thymidine kinase to add a phosphate molecule to it—essentially turning the key to unlock the medicine’s power ^[4][2]. Because healthy, uninfected cells do not contain viral thymidine kinase, the drug remains largely inactive in those areas ^[5]. Once the virus takes that first step, the baby’s own cellular enzymes finish the activation process, concentrating the active medication inside the HSV-infected cells ^[4][6].

However, acyclovir is not entirely harmless to healthy tissues. It can crystallize in the kidneys, causing kidney injury, and prolonged use can lead to low white blood cell counts (neutropenia) ^[7]. Because of this, the care team will closely monitor the baby’s hydration, urine output, serum creatinine (a kidney lab test), and blood counts, adjusting the dose if kidney function changes ^[1][7]. In rare cases, the virus can develop mutations making it resistant to acyclovir, though this is uncommon ^[8][9].

Treatment Course: Why Duration Matters

For neonatal HSV, rapid IV treatment is required to quickly achieve high drug levels in the blood and tissues ^[7]. The duration of this hospital IV treatment depends strictly on which category of HSV the baby has:

• Skin, Eye, and Mouth (SEM) disease is generally treated with IV acyclovir for at least 14 days ^[10].
• Central Nervous System (CNS) disease (brain involvement) or Disseminated disease (multiple organs involved) requires a longer course of at least 21 days ^[10][11].

Treatment response is not judged by visible symptom improvement alone. For CNS disease, the medical team will typically perform a repeat lumbar puncture to check the cerebrospinal fluid (CSF) with an HSV PCR test near the end of the 21 days ^[10]. If the virus is still detected, the IV treatment is extended ^[10].

After the IV course is successfully completed, infants are generally transitioned to an oral acyclovir suppression therapy for six months ^[10][11]. This oral medicine does not eliminate the virus—which remains dormant in the body—but it helps reduce the risk of recurrences and supports better developmental outcomes ^[10]. During this time, the baby’s blood counts (especially neutrophil counts) and kidney function will continue to be monitored ^[11].